On June 2, 2025, BioNTech SE announced a global partnership with Bristol Myers Squibb for co-developing its bispecific antibody BNT327 aimed at multiple solid tumor types. This collaboration signifies a major step in advancing cancer treatment.
AI Assistant
BIONTECH SE
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.